

# De invloed van Gaviscon op de acid pocket en zure reflux.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON25536

### Source

NTR

### Health condition

GERD

Gastro-esophageal reflux disease

GORZ

gastro-oesofageale reflux ziekte

## Sponsors and support

**Primary sponsor:** Prof. dr. G.E. Boeckxstaens

Academic Medical Center

**Source(s) of monetary or material Support:** Prof. dr. G.E. Boeckxstaens

Academic Medical Center

## Intervention

## Outcome measures

### Primary outcome

Primary outcome is the number of acid reflux episodes detected on pH-impedance measurements.

## Secondary outcome

Secondary outcomes are postprandial esophageal acid exposure, the rate of acid versus non acid reflux events, the number of non acid reflux events and the position of the acid pocket, relative to the crural diaphragm.

## Study description

### Background summary

The gastric acid pocket is the most important source of refluxate. It is hypothesized that very commonly used alginate-antacid formulations form a floating raft on top of the acid pocket. This is however never visualized in vivo. To visualize the alginate raft formation and to assess the effect of this raft formation on reflux parameters, we aimed to perform a randomised controlled study in which we compared Gaviscon, a alginate-antacid formulation to Antagel, a commonly used antacid.

We will compare these two over the counter medications in one postprandial measurement using pH-impedance testing to detect reflux episodes.

### Study objective

We hypothesize that after alginate intake a raft is formed in the proximal stomach proximal of the gastric acid pocket, and that this raft affects the gastric acid pocket regarding acidity, position and size leading to less acid reflux events.

### Study design

Patients undergo 1 postprandial measurement.

### Intervention

1. The use of proton pump inhibitors has to be stopped 5-7 days prior to the study day;
2. On the study day, 350MBq Tc-pertechnetate is injected intravenously;
3. Randomized single oral administration of either 10 mL Gaviscon (Indium-labelled) or 10 mL Antagel;
4. Esophageal high-resolution manometry/pH-manometry to detect reflux eipsodes during 2 postprandial hours;
5. Scintigraphy.

## Contacts

### Public

Academic Medical Center (AMC), Department of Gastroenterology, C2-328,  
P.O. Box 22660  
G.E.E. Boeckxstaens  
Meibergdreef 9  
Amsterdam 1100 DD  
The Netherlands  
+31 (0)20 5667375

### Scientific

Academic Medical Center (AMC), Department of Gastroenterology, C2-328,  
P.O. Box 22660  
G.E.E. Boeckxstaens  
Meibergdreef 9  
Amsterdam 1100 DD  
The Netherlands  
+31 (0)20 5667375

## Eligibility criteria

### Inclusion criteria

1. GERD confirmed by pH-impedance (ph<4 in > 4,5 % of time or positive symptom association), or in patients with reflux esophagitis;
2. Written informed consent;
3. 18-75 years.

### Exclusion criteria

1. Surgery of the gastrointestinal tract other than appendectomy;
2. Inability to stop the use of proton pump inhibitors for one week;
3. Participation in another study with exposure to radiation;
4. Participation in another study within the last year;

5. Long segment of Barrett's epithelium.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)
Control:	Active

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-06-2012
Enrollment:	16
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	04-09-2012
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL3451
NTR-old	NTR3602
Other	MEC / CCMO : 11/279 / NI37764.018.11;
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Study results

### Summary results

Previous publications on this subject from our group:

<br><br>

Beaumont H, Bennink RJ, de Jong J et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010;59(4):441-51.

<br><br>

Rohof WO, Bennink RJ, Hirsch DP et al. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut. 2012 Jan 20. [Epub ahead of print].